FDA 510(k) Clearance Granted for Endomag’s Breast Tumor Localization System
Monday, 4 April, 2016
Endomag, the cancer healthcare company, announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Magseed® magnetic marker for use with Sentimag®.
Expanding its solutions for cancer clinicians and patients, Endomag’s Magseed® is designed to...
Endomag completes patient enrolment of U.S. pivotal trial for Sentimag and Sienna+
Tuesday, 8 December, 2015
Endomag, the cancer healthcare company, has completed enrolment in the pivotal multi-centre U.S. trial of its Sentimag® and Sienna+® system for staging breast cancer.
The six clinical sites enrolled 160 subjects in 10 months, completing ahead of schedule, and included some of the world’s...
Endomag scoops business award for innovation
Wednesday, 28 October, 2015
Cancer healthcare company Endomag has won an Innovate UK SME Innovation Award for innovation leading to productivity improvement.
The House of Commons event awarded Endomag’s nanoscale magnetic tracer system, Sentimag® and Sienna+®, that locates lymph nodes as part of a sentinel lymph...
Lord Sainsbury opens Endomag’s Cambridge headquarters
Thursday, 18 June, 2015
The cancer healthcare company Endomag has officially opened its Cambridge headquarters after relocating to larger offices in the prestigious Jeffreys Building, St John’s Innovation Park, due to its rapid growth.
Lord David Sainsbury of Turville, Chancellor of the University of Cambridge,...
Endomag selected as finalist for top engineering award
Wednesday, 20 May, 2015
Cancer healthcare company Endomag has been revealed as a finalist for the UK’s most prestigious engineering award.
Endomag, which was shortlisted for its innovative breast cancer staging diagnostic system Sentimag® and Sienna+®, is one of three companies up for the MacRobert Award from...